Phase III Long-Term Extension Study With Dexpramipexole (EXHALE-5)
An Open-Label Long-Term Phase III Extension Study to Assess the Long-Term Safety and Tolerability of Dexpramipexole in Participants With Severe Eosinophilic Asthma
Sponsor: Areteia Therapeutics
Terminated
Program stopped due to the benefit risk profile no longer supports further development in the intended patient population.
Other terminated trials from Areteia Therapeutics
More terminations from Areteia Therapeutics
Other Eosinophilic Asthma trials with similar outcome
Listed as NCT06388889, this PHASE3 trial focuses on Eosinophilic Asthma and remains terminated or withdrawn. Sponsored by Areteia Therapeutics, it has been updated 11 times since 2024, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE3
Status: Enrolling By Invitation → Active Not Recruiting
-
Oct 2025 — Dec 2025 [monthly]
Enrolling By Invitation PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Enrolling By Invitation PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Enrolling By Invitation PHASE3
▶ Show 6 earlier versions
-
Jun 2025 — Jul 2025 [monthly]
Enrolling By Invitation PHASE3
-
May 2025 — Jun 2025 [monthly]
Enrolling By Invitation PHASE3
-
Oct 2024 — May 2025 [monthly]
Enrolling By Invitation PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Enrolling By Invitation PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Enrolling By Invitation PHASE3
-
May 2024 — Jul 2024 [monthly]
Enrolling By Invitation PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Areteia Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .